Intravenous immunoglobulins in autoimmune and inflammatory diseases: A mechanistic perspective

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 497-506

  Sibéril, Sophie ^a   Elluru, Sriramulu ^a,b   Graff Dubois, Stéphanie ^a   Negi, Vir Singh ^c   Delignat, Sandrine ^a   Mouthon, Luc ^d   Lacroix Desmazes, Sébastien ^a   Kazatchkine, Michel D ^a   Bayary, Jagadeesh ^a   Kaveri, Srini V ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^c JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^d Université Paris Descartes ^*  (France)

Author keywords

Autoimmunity; Immune modulation; Inflammation; Intravenous immunoglobulins

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTIMITOTIC AGENT; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; FAS ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

AGAMMAGLOBULINEMIA; APOPTOSIS; AUTOIMMUNE DISEASE; COMPLEMENT SYSTEM; CONFERENCE PAPER; DRUG EFFECT; DRUG MEGADOSE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATORY DISEASE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; SUBSTITUTION THERAPY;

EID: 35748957162     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.052     Document Type: Conference Paper

References (63)

1. KAZATCHKINE, M.D. & S.V. KAVERI. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345: 747-755.
2. JOLLES, S., W.A. SEWELL & S.A. MISBAH. 2005. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. 142: 1-11.
3. ORANGE, J.S., E.M. HOSSNY, C.R. WEILER, et al. 2006. Use of intravenous immunoglobulin in human disease: a reviewof evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117: S525-S553.
4. GOLD, R., M. STANGEL & M.C. DALAKAS. 2007. Drug insight: the use of intravenous immunoglobulin in neurology: therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3: 36-44.
5. SHERER, Y. & Y. SHOENFELD. 2006. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun. Rev. 5: 153-155.
6. SAPIR, T., M. BLANK & Y. SHOENFELD. 2005. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann. N.Y. Acad. Sci. 1051: 743-778.
7. SAPIR, T. & Y. SHOENFELD. 2005. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin. Rev. Allergy Immunol. 29: 185-199.
8. GHIELMETTI, M., M. BELLIS, M.O. SPYCHER, et al. 2006. Gene expression profiling of the effects of intravenous immunoglobulin in human whole blood. Mol. Immunol. 43: 939-949.
9. RAJU, R. & M.C. DALAKAS. 2005. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128: 1887-1896.
10. DEBRE, M., M.C. BONNET, W.H. FRIDMAN, et al. 1993. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342: 945-949.
11. BUSSEL, J.B. 2000. Fc receptor blockade and immune thrombocytopenic purpura. Semin. Hematol. 37: 261-266.
12. SAMUELSSON, A., T.L. TOWERS & J.V. RAVETCH. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
13. KANEKO, Y., F. NIMMERJAHN, M.P. MADAIO, et al. 2006. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203: 789-797.
14. BORUCHOV, A.M., G. HELLER, M.C. VERI, et al. 2005. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115: 2914-2923.
15. SIRAGAM, V., A.R. CROW, D. BRINC, et al. 2006. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat. Med. 12: 688-692.
16. HAMERMAN, J.A. & L.L. LANIER. 2006. Inhibition of immune responses by ITAM-bearing receptors. Sci. STKE 2006: re1.
17. PARK-MIN, K.H., N.V. SERBINA, W. YANG, et al. 2007. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26: 67-78.
18. AKILESH, S., S. PETKOVA, T.J. SPROULE, et al. 2004. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113: 1328-1333.
19. KAZATCHKINE, M.D., G. DIETRICH, V. HUREZ, et al. 1994. V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol. Rev. 139: 79-107.
20. SHERER, Y., Y. LEVY & Y. SHOENFELD. 2000. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 39: 421-426.
21. ABEDI, M.R., L. HAMMARSTROM, U. BROOME, et al. 1996. Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Clin. Exp. Immunol. 105: 266-273.
22. VASSILEV, T., M. YAMAMOTO, A. AISSAOUI, et al. 1999. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. J. Immunol. 29: 2436-2442.
23. SAMI, N., K.C. BHOL & A.R. AHMED. 2002. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin. Immunol. 105: 192-198.
24. SHERER, Y. & Y. SHOENFELD. 2006. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2: 99-106.
25. HOFFMANN, M., M.M.UTTENREUTHER-FISCHER, H. LERCH, et al. 2000. IVIG-bound IgG and IgM cloned by phage display from a healthy individual reveal the same restricted germ-line gene origin as in autoimmune thrombocytopenia. Clin. Exp. Immunol. 121: 37-46.
26. OSEI, A., M.M. UTTENREUTHER-FISCHER, H. LERCH, et al. 2000. Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin. Arthritis Rheum. 43: 2722-2732.
27. LEUCHT, S., M.M. UTTENREUTHER-FISCHER, G. GAEDICKE, et al. 2001. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Clin. Immunol. 99: 18-29.
28. ANDERSSON, U., L. BJORK, S.U. SKANSEN, et al. 1994. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol. Rev. 139: 21-42.
29. ANDERSSON, U.G., L. BJORK, U. SKANSEN- SAPHIR, et al. 1993. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79: 211-216.
30. RUIZ DE SOUZA, V., M.P. CARRENO, S.V. KAVERI, et al. 1995. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur. J. Immunol. 25: 1267-1273.
31. SHARIEF, M., D. INGRAM, M. SWASH, et al. 1999. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 52: 1833-1838.
32. GUPTA, M., G.J. NOEL, M. SCHAEFER, et al. 2001. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J. Clin. Immunol. 21: 193-199.
33. BASTA, M., L.F. FRIES & M.M. FRANK. 1991. High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77: 376-380.
34. MOLLNES, T.E., K. HOGASEN, C. DE CAROLIS, et al. 1998. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand. J. Immunol. 48: 312-317.
35. LUTZ, H.U., P. STAMMLER, E. JELEZAROVA, et al. 1996. High doses of immunoglobulin Gattenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 88: 184-193.
36. LUTZ, H. U., P. STAMMLER, V. BIANCHI, et al. 2004. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103: 465-472.
37. VAN SCHAIK, I.N., I. LUNDKVIST, M. VERMEULEN, et al. 1992. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J. Clin. Immunol. 12: 325-334.
38. VAN SCHAIK, I.N., M. VERMEULEN & A. BRAND. 1994. In vitro effects of polyvalent immunoglobulin for intravenous use. J. Neurol. Neurosurg. Psychiatr. 57(Suppl): 15-17.
39. WARRINGTON, R.J. & K.E. LEWIS. 2007. Biologically active anti-nerve growth factor antibodies in commercial intravenous gammaglobulin. J. Autoimmun.
40. VIARD, I., P. WEHRLI, R. BULLANI, et al. 1998. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282: 490-493.
41. PRASAD, N.K., G. PAPOFF, A. ZEUNER, et al. 1998. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J. Immunol. 161: 3781-3790.
42. ALTZNAUER, F., S. VON GUNTEN, P. SPATH, et al. 2003. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J. Allergy Clin. Immunol. 112: 1185-1190.
43. MARCHALONIS, J.J., H. KAYMAZ, F. DEDEOGLU, et al. 1992. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor ß chain. Proc. Natl. Acad. Sci. USA 89: 3325-3329.
44. SVENSON, M., M.B. HANSEN, C. ROSS, et al. 1998. Antibody to granulocytemacrophage colony-stimulating factor is a dominant anti-cytokine activity in Human IgG preparations. Blood 91: 2054-2061.
45. BENDTZEN, K., M.B. HANSEN, C. ROSS, et al. 1998. High-avidity autoantibodies to cytokines. Immunol. Today 19: 209-211.
46. VASSILEV, T., C. GELIN, S.V. KAVERI, et al. 1993. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin. Exp. Immunol. 92: 369-372.
47. HUREZ, V., S.V. KAVERI, A. MOUHOUB, et al. 1994. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Therap. Immunol. 1: 269-278.
48. KAVERI, S., T. VASSILEV, V. HUREZ, et al. 1996. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J. Clin. Invest. 97: 865-869.
49. VASSILEV, T., M.D. KAZATCHKINE, J.P. DUONG VANHUYEN, et al. 1999. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93: 3624-3631.
50. BOUHLAL, H., H. HOCINI, C. QUILLENT- GREGOIRE, et al. 2001. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J. Immunol. 166: 7606-7611.
51. BAYRY, J., S. LACROIX-DESMAZES, V. DONKOVA-PETRINI, et al. 2004. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 101: 14210-14215.
52. SIGMAN, K., F. GHIBU, W. SOMMERVILLE, et al. 1998. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J. Allergy Clin. Immunol. 102: 421-427.
53. DE GRANDMONT, M. J., C. RACINE, A. ROY, et al. 2003. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101: 3065-3073.
54. BAYRY, J., S. LACROIX-DESMAZES, C. CARBONNEIL, et al. 2003. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101: 758-765.
55. BAYRY, J., S. LACROIX-DESMAZES, S. DELIGNAT, et al. 2003. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 48: 3497-3502.
56. BAYRY, J., O. HERMINE, D.A. WEBSTER, et al. 2005. Common variable immunodeficiency: the immune system in chaos. Trends Mol. Med. 11: 370-376.
57. BAYRY, J., S. LACROIX-DESMAZES, M.D. KAZATCHKINE, et al. 2004. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 104: 2441-2443.
58. BAYRY, J., S. LACROIX-DESMAZES, O. HERMINE, et al. 2005. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am. J. Med. 118: 1439-1440.
59. BAYRY, J., M.D. KAZATCHKINE & S.V. KAVERI. 2007. Shortage of human intravenous immunoglobulin: reasons and possible solutions. Nat. Clin. Pract. Neurol. 3: 120-121.
60. AHMED, A.R., Z. SPIGELMAN, L.A. CAVACINI, et al. 2006. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl J. Med. 355: 1772-1779.
61. HUREZ, V., M.D. KAZATCHKINE, T. VASSILEV, et al. 1997. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90: 4004-4013.
62. BAZIN, R., R. LEMIEUX & T. TREMBLAY. 2006. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br. J. Haematol. 135: 97-100.
63. KANEKO, Y., F. NIMMERJAHN & J.V. RAVETCH. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.